Institutional members access full text with Ovid®

Share this article on:

Evolution of the Gynecologic Oncology Group Protocols in the Treatment of Epithelial Ovarian Cancer

SEAMON, LEIGH G. DO, MPH*; RICHARDSON, DEBRA L. MD; COPELAND, LARRY J. MD

Clinical Obstetrics & Gynecology: March 2012 - Volume 55 - Issue 1 - p 131–155
doi: 10.1097/GRF.0b013e318248050d
Ovarian Cancer

This chapter reviews some of the sentinel Gynecologic Oncology Group (GOG) ovarian trials, describes their rationale, provides summary tables for reference, and is organized into early ovarian cancer (GOG 1, 7601, 7602, 95, 157, 175, 212), advanced ovarian cancer optimal (2, 25, 52, 104, 114, 158, 172, 182, 178, 212, 252), and suboptimal disease (3, 22, 47, 97, 111, 162, 182, 218, 252, 262).

*Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, Spectrum Health Medical Group and Michigan State University College of Human Medicine, Grand Rapids, Michigan

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Texas Southwestern Medical Center, Dallas, Texas

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Center and Solove Research Institute, Columbus, Ohio

The authors declare that they have nothing to disclose.

Correspondence: Leigh G. Seamon, DO, MPH, Gynecologic Oncology, Lemmen-Holton Cancer Pavilion, Suite 2220, Grand Rapids, MI. E-mail: Leigh.Seamon@spectrumhealth.org

© 2012 Lippincott Williams & Wilkins, Inc.